Healthcare Stocks on Investors' Radar -- Sophiris Bio, Catalyst Pharma, Neurocrine Biosciences, and Capital Senior Living

NEW YORK, December 13, 2016 /PRNewswire/ --

This morning, Stock-Callers.com has lined up the following equities for evaluation: Sophiris Bio Inc. (NASDAQ: SPHS), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Capital Senior Living Corp. (NYSE: CSU). These companies belong to the Healthcare sector, which, on Monday, December 12^th, 2016, extended its gains from late last week. As per a NASDAQ report, the NYSE Health Care Index posted a 0.5% advance, while shares of health care companies in the S&P 500 rose over 0.5% as a group. Learn more about these stocks by downloading their comprehensive and free reports at:

http://stock-callers.com/registration

Sophiris Bio 

On Monday, shares in La Jolla, California-based Sophiris Bio Inc. recorded a trading volume of 2.03 million shares, which was above their three months average volume of 994,900 shares. The stock ended the day at $2.92, jumping 7.35% from the last trading session. The Company's shares have advanced 1.74% in the last one month, 3.91% in the previous three months, and 64.04% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.45% and 15.18%, respectively. Furthermore, shares of Sophiris Bio, which focuses on the development of products for the treatment of urological diseases, have a Relative Strength Index (RSI) of 55.42.

On November 9^th, 2016, Sophiris Bio reported a net loss of $4.3 million ($0.17 per share) for Q3 2016 compared to a net loss of $3.7 million ($0.22 per share) for Q3 2015. At September 30, 2016, the company had cash, cash equivalents, and securities available-for-sale of $31.3 million and net working capital of $29.8 million. The company expects that its cash and cash equivalents will be sufficient to fund the operations into Q2 2018. SPHS complete research report is just a click away and free at:

http://stock-callers.com/registration/?symbol=SPHS

Catalyst Pharma 

Coral Gables, Florida-based Catalyst Pharmaceuticals Inc.'s stock saw a decline of 1.69%, finishing yesterday's session at $1.16 with a total trading volume of 346,258 shares. The Company's shares have gained 10.48% in the last month and 19.59% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 0.94% and 20.68%, respectively. Additionally, shares of Catalyst Pharmaceuticals, which focuses on the development and commercialization of therapies for people with rare debilitating diseases, have an RSI of 50.49.

On December 8^th, 2016, Catalyst Pharmaceuticals provided an update on its clinical trial with amifampridine phosphate in patients with congenital myasthenic syndromes (CMS). The company noted that after discussions with the US FDA, the study has been expanded beyond pediatric patients to include adult CMS patients and the enrollment size has been increased to approximately 20 patients. The complimentary report on CPRX can be downloaded at:

http://stock-callers.com/registration/?symbol=CPRX

Neurocrine Biosciences 

Shares in San Diego, California headquartered Neurocrine Biosciences Inc. ended Monday's session 0.84% higher at $42.01 with a total trading volume of 675,936 shares. The stock is trading 9.08% below its 200-day moving average. Shares of the Company, which discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the US, have an RSI of 37.99.

On November 22^nd, 2016, research firm Oppenheimer initiated a 'Perform' rating on the Company's stock.

On November 29^th, 2016, Neurocrine Biosciences announced that the Psychopharmacologic Drugs Advisory Committee of the US FDA will review data included in the New Drug Application (NDA) of INGREZZATM (valbenazine) for the treatment of tardive dyskinesia on February 16^th, 2017. The FDA has granted Priority Review status to the INGREZZA NDA with a Prescription Drug User Fee Act (PDUFA) target action date of April 11^th, 2017. The NDA for INGREZZA includes the results from the Kinect 2 and Kinect 3 clinical trials which evaluated over 330 tardive dyskinesia patients. Data from these studies along with the results from another 18 clinical trials, extensive preclinical testing and drug manufacturing data were included in the NDA submission. Sign up for your complimentary research report on NBIX at:

http://stock-callers.com/registration/?symbol=NBIX

Capital Senior Living 

At the close, Dallas, Texas headquartered Capital Senior Living Corp.'s stock dropped 1.88%, finishing at $16.67. A total volume of 233,801 shares was traded. The Company's shares have gained 16.66% in the past month. The stock is trading 7.04% above its 50-day moving average. Additionally, shares of Capital Senior Living, which together with its subsidiaries, owns, operates, develops, and manages senior living communities in the US, have an RSI of 64.60.

As per notes files with the SEC dated November 15^th, 2016, Keith N. Johannessen, the President and COO of Capital Senior Living on November 11^th, 2016, announced his intent to take a medical leave of absence commencing immediately. The Company currently anticipates that Mr. Johannessen will return to work during Q1 2017. Get free access to your research report on CSU at:

http://stock-callers.com/registration/?symbol=CSU

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA